Ключевые слова
Как цитировать
Аннотация
В связи с растущей заболеваемостью и распространенностью злокачественных новообразований (ЗНО) на территории РФ появление новых медицинских технологий является важной составляющей борьбы с данными заболеваниями. Одной из новых разработок для лечения таких заболеваний являются агностические препараты, уникальность которых связана с механизмом действия, направленным на лечение ЗНО независимо от локализации опухоли при наличии определенного биомаркера. В настоящее время существует 3 агностических лекарственных препарата (ЛП) — энтректиниб, ларотректиниб, достарлимаб. Подавляющая часть клинических исследований агностических ЛП является когортными несравнительными, что обуславливает ряд проблем при рассмотрении данных ЛП к регистрации и возмещению как в РФ, так и в зарубежных странах. Несмотря на данное ограничение, рассматриваемые ЛП зарегистрированы или чаще условно зарегистрированы в зарубежных странах (США, Канада, страны Европейского Союза, Австралия, Япония). Агностические ЛП включены в зарубежные клинические рекомендации (КР) и финансируются за счет бюджетных средств в ряде зарубежных стран, несмотря на ограниченные данные по клинической эффективности. Данная тенденция обусловлена необходимостью удовлетворить медицинские потребности в терапии заболеваний, являющихся жизнеугрожающими или приводящими к фатальным последствиям для пациента.
Библиографические ссылки
Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой Злокачественные новообразования в России в 2021 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России. 2022:252 [Kaprin AD, Starinsky VV, Shakhzadova AO, editors. Malignant neoplasms in Russia in 2021 (morbidity and mortality). Moscow:P.A. Herzen MNIOI - branch of FGBU «NMRC Radiology» of the Ministry of Health of Russia. 2022:252 (In Russ.)].
Prescribing information ROZLYTREK (entrectinib) capsules, for oral use [Internet]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf (accessed: 01.08.2022).
Государственный реестр лекарственных средств: Витракви® [Internet]. Available from: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=f44bb994-1a9c-4c49-ae30-80ca9bdc21b4 (accessed: 01.08.2022).
Prescribing information JEMPERLI (dostarlimab-gxly) injection, for intravenous use [Internet]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761174s002lbl.pdf (accessed: 01.08.2022).
Gronchi A, Miah AB, Dei Tos, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆. Annals of Oncology. 2021;32(11):1348-65. http://dx.doi.org/10.1016/j.annonc.2021.07.006.
Casali PG, Blay JY, Abecassis N, et al. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2022;33(1):20-33. http://dx.doi.org/10.1016/j.annonc.2021.09.005.
Filetti S, Durante C, Hartl DM, et al. ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer. Annals of Oncology. 2022;33(7):674-84. http://dx.doi.org/10.1016/j.annonc.2022.04.009.
Hendriks LE, Kerr KM, Menis J, et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology [Internet]. 2023;34(4):339-57. http://dx.doi.org/10.1016/j.annonc.2022.12.009. Available from: https://www.esmo.org/guidelines/guidelines-by-topic/lung-and-chest-tumours/clinical-practice-living-guidelines-metastatic-non-small-cell-lung-cance (accessed: 01.08.2022).
Gajjar A, Mahajan A, Abdelbaki M, et al. Pediatric central nervous system cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology [Internet]. J Natl Compr Canc Netw. 2022;20(12):1339-1362. Available from: https://www.nccn.org/professionals/physician_gls/pdf/ped_cns.pdf (accessed: 01.08.2022).
von Mehren M, Kane JM, Riedel RF, et al. NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 1.2022 [Internet]. J Natl Compr Canc Netw. 2022;20(11):1204-14. http://dx.doi.org/10.6004/jnccn.2022.0058. Available from: https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf (accessed: 01.08.2022).
Swetter SM, Johnson D, Thompson JA, et al. NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2023. J Natl Compr Canc Netw [Internet]. 2022;231. Available from: https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf (accessed: 01.08.2022).
Ettinger DS, Stevenson MM, Ahn D, et al. NCCN Guidelines® Insights: Occult Primary (Cancer of Unknown Primary [CUP]). Version 3.2023 [Internet]. 2022;76. Available from: https://www.nccn.org/professionals/physician_gls/pdf/occult.pdf (accessed: 01.08.2022).
Kumar ShK, Callander NS, Adekola K, et al. Breast Cancer, Version 4.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;107.
Ajani JA, D'Amico TA, Bentrem DJ, et al. Esophageal and Esophagogastric Junction Cancers, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023;172 [Internet]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf (accessed: 01.08.2022).
Pfister DG, Spencer Sh, Adkins D, et al. Head and Neck Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023;250 [Internet]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf (accessed: 01.08.2022).
Benson AB, Venook AP, Al-Hawary MM, et al. Small bowel adenocarcinoma, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023;54 [Internet]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/small_bowel.pdf (accessed: 01.08.2022).
Abu-Rustum NR, Yashar CM, Arend R, et al. Uterine Neoplasms, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(8):888-895 [Internet]. https://doi.org/10.6004/jnccn.2021.0038. Available from: https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf (accessed: 01.08.2022).
Ajani JA, D'Amico TA, Bentrem DJ, et al. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(2):167-192 [Internet]. https://doi.org/10.6004/jnccn.2022.0008. Available from: https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf (accessed: 01.08.2022).
Go RS, Jacobsen E, Baiocchi R, et al. Histiocytic Neoplasms, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 [Internet]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf (accessed: 01.08.2022).
Ettinger DS, Wood DE, Aisner DL, et al. Non-Small Cell Lung Cancer, Version 3.2022. NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 [Internet]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf (accessed: 01.08.2022).
Benson AB, Venook AP, Al-Hawary, et al. Rectal Cancer, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 [Internet]. https://doi.org/10.6004/jnccn.2022.0051. Available from: https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf (accessed: 01.08.2022).
Benson AB, Venook AP, Al-Hawary, et al. Colon Cancer, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 [Internet]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf (accessed: 01.08.2022).
Garcia-Foncillas J, Bokemeyer C, Italiano A, et al. Indirect treatment comparison of Larotrectinib versus Entrectinib in treating patients with TRK gene fusion cancers. Cancers (Basel). 2022;14(7):1793. https://doi.org/10.3390/cancers14071793.
Pollack M, Keating K, Wissinger E, et al. Transforming approaches to treating TRK fusion cancer: historical comparison of larotrectinib and histology-specific therapies. Curr Med Res Opin. 2021;37(1):59-70. https://doi.org/10.1080/03007995.2020.1847057.
Chu P, Antoniou M, Bhutani MK, et al. Matching-adjusted indirect comparison: entrectinib versus crizotinib in ROS1 fusion-positive non-small cell lung cancer. J Comp Eff Res. 2020;9(12):861-876. https://doi.org/10.2217/cer-2020-0063.
Doebele RC, Perez L, Trinh H, et al. Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data in ROS1+ NSCLC. J Comp Eff Res. 2021;10(17):1271-1282. https://doi.org/10.2217/cer-2021-0131.
Krebs MG, Blay JY, Le Tourneau C, et al. Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications. ESMO Open. 2021;6(2):100072. https://doi.org/10.1016/j.esmoop.2021.100072.
Oaknin A, Gilbert L, Tinker AV, et al. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study. J Immunother Cancer. 2022;10(1):e003777. https://doi.org/10.1136/jitc-2021-003777.
Patnaik A, Weiss GJ, Rasco DW, et al. Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial. Cancer Chemother Pharmacol. 2022;89(1):93-103. https://doi.org/10.1007/s00280-021-04358-3.
Drilon A, Tan DSW, Lassen UN, et al. Efficacy and safety of Larotrectinib in patients with tropomyosin receptor kinase fusion-positive lung cancers. JCO Precis Oncol. 2022;6:e2100418. https://doi.org/10.1200/PO.21.00418.
Hong DS, Bauer TM, Lee JJ, et al. Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study. Ann Oncol. 2019;30(2):325-331. https://doi.org/10.1093/annonc/mdy539.
Laetsch TW, DuBois SG, Mascarenhas L, et al. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. Lancet Oncol. 2018;19(5):705-714. https://doi.org/10.1016/S1470-2045(18)30119-0.
Drilon A, Laetsch TW, Kummar S, et al. Efficacy of Larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378(8):731-739. https://doi.org/10.1056/NEJMoa1714448.
Le X, Baik C, Bauman J, et al. Larotrectinib Treatment for patients with TRK fusion-positive salivary gland cancers. Oncologist. 2022:oyac080. https://doi.org/10.1093/oncolo/oyac080.
Waguespack SG, Drilon A, Lin JJ, et al. Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. Eur J Endocrinol. 2022;186(6):631-643. https://doi.org/10.1530/EJE-21-1259.
Doz F, van Tilburg CM, Geoerger B, et al. Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors. Neuro Oncol. 2022;24(6):997-1007. https://doi.org/10.1093/neuonc/noab274.
Hong DS, DuBois SG, Kummar S, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol. 2020;21(4):531-540. https://doi.org/10.1016/S1470-2045(19)30856-3.
McDermott R, van Tilburg CM, Farago AF, et al. 1955P Survival benefits of larotrectinib in an integrated dataset of patients with TRK fusion cancer. Annals of Oncology. 2020;31:S1101-2. http://dx.doi.org/10.1016/j.annonc.2020.08.1347.
Desai AV, Robinson GW, Gauvain K, et al. Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG). Neuro Oncol. 2022;24(10):1776-1789. https://doi.org/10.1093/neuonc/noac087.
Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020;21(2):271-282. https://doi.org/10.1016/S1470-2045(19)30691-6.
Dziadziuszko R, Krebs MG, De Braud F, et al. Updated integrated analysis of the efficacy and safety of Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small-cell lung cancer. J Clin Oncol. 2021;39(11):1253-1263. https://doi.org/10.1200/JCO.20.03025.
Drilon A, Siena S, Dziadziuszko R, et al. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020;21(2):261-270. https://doi.org/10.1016/S1470-2045(19)30690-4.
Drilon A, Siena S, Ou SI, et al. Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 2017;7(4):400-409. https://doi.org/10.1158/2159-8290.CD-16-1237.
Demetri GD, De Braud F, Drilon A, et al. Updated integrated analysis of the efficacy and safety of Entrectinib in patients with NTRK fusion-positive solid tumors. Clin Cancer Res. 2022;28(7):1302-1312. https://doi.org/10.1158/1078-0432.CCR-21-3597.
Porta M, ed. A Dictionary of Epidemiology (6 ed). 2014 [Internet]. http://dx.doi.org/10.1093/acref/9780199976720.001.0001. Available from: https://www.oxfordreference.com/view/10.1093/acref/9780199976720.001.0001/acref-9780199976720-e-2306 (accessed: 07.09.2022).
Доступ к новым лекарственным средствам в Европе: технический доклад о политических инициативах и возможностях для сотрудничества и исследований. Всемирная организация здравоохранения. Европейское региональное бюро. 2015;180. [World Health Organization. Regional Office for Europe. Access to new medicines in Europe: technical review of policy initiatives and opportunities for collaboration and research. 2015;180. World Health Organization. Regional Office for Europe. (In Russ.)]. Available from: https://iris.who.int/bitstream/handle/10665/365424/WHO-EURO-2015-3211-42969-67837-rus.pdf?sequence=1&isAllowed=y.
Государственный реестр лекарственных средств [Internet]. [State Register of Medicines (In Russ.)]. Available from: https://grls.rosminzdrav.ru/Default.aspx (accessed: 03.04.2023).
European Medicines Agency [Internet]. Available from: https://www.ema.europa.eu/en (accessed: 03.04.2023).
U.S. Food and Drug Administration. [Internet]. Available from: https://www.fda.gov/ (accessed: 03.04.2023).
Therapeutic Goods Administration (TGA) | Australian Government Department of Health. [Internet]. Available from: https://www.tga.gov.au/ (accessed: 03.04.2023).
Government of Canada. [Internet]. Canada.ca. The official website of the Government of Canada. Available from: https://www.canada.ca/en.html (accessed: 03.04.2023).
Pharmaceuticals and Medical Devices Agency [Internet]. Available from: https://www.pmda.go.jp/english/ (accessed: 03.04.2023).
Institute for Quality and Efficiency in Health Care | IQWiG.de [Internet]. Available from: https://www.iqwig.de/en/ (accessed: 03.04.2023).
Haute Autorité de Santé - Professionnels [Internet]. Available from: https://www.has-sante.fr/ (accessed: 03.04.2023).
Canada’s Drugs and Health Technology Agency. CADTH. [Internet]. Available from: https://www.cadth.ca/ (accessed: 03.04.2023).
The National Institute for Health and Care Excellence. NICE [Internet]. NICE. Available from: https://www.nice.org.uk/ (accessed: 03.04.2023).
Tandvårds- och läkemedelsförmånsverket TLV / The Dental and Pharmaceutical Benefits Agency. [Internet]. TLV. Available from: https://www.tlv.se/in-english.html (accessed: 03.04.2023).
Danish Medicines Council [Internet]. Medicinradet. Available from: https://medicinraadet.dk/om-os/in-english (accessed: 03.04.2023).
Healthcare Improvement Scotland [Internet]. The Scottish Medicines Consortium (SMC). Available from: https://www.scottishmedicines.org.uk/ (accessed: 03.04.2023).
Мельникова Л.С., Федяев Д.В., Герасимова К.В. Инновационные методы лекарственного обеспечения: соглашения о разделении рисков. Злокачественные опухоли. 2016;(4 спецвыпуск 1):99-102 [Melnikova LS, Fedyaev DV, Gerasimova KV. Innovative methods of drug provision: risk-sharing agreements. Malignant tumors. 2016;4(special issue 1):99-102 (In Russ.)].
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency. Technology appraisal guidance [TA779]. [Internet]. National Institute for Health and Care Excellence NICE. 2022. Available from: https://www.nice.org.uk/guidance/ta779/chapter/1-Recommendations (accessed: 03.04.2023).
Larotrectinib for treating NTRK fusion-positive solid tumours. Technology appraisal guidance [TA630] [Internet]. National Institute for Health and Care Excellence NICE. 2020. Available from: https://www.nice.org.uk/guidance/ta630 (accessed: 03.04.2023).
Larotrectinib. [Internet]. CADTH. 2020 [updated 2021]. Available from: https://www.cadth.ca/larotrectinib (accessed: 03.04.2023).
Entrectinib for treating NTRK fusion-positive solid tumours. Technology appraisal guidance [TA644] [Internet]. National Institute for Health and Care Excellence NICE. 2020. Available from: https://www.nice.org.uk/guidance/ta644 (accessed: 03.04.2023).
Entrectinib (Rozlytrek). [Internet]. Scottish Medicines Consortium. 2021. Available from: https://www.scottishmedicines.org.uk/medicines-advice/entrectinib-rozlytrek-full-smc2295/ (accessed: 03.04.2023).
Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer. Technology appraisal guidance [TA643] [Internet]. National Institute for Health and Care Excellence NICE. 2020. Available from: https://www.nice.org.uk/guidance/ta643/chapter/1-Recommendations (accessed: 03.04.2023).
Entrectinib (Rozlytrek) for ROS1-positive Non-Small Cell Lung Cancer CADTH. 2020 [updated 2021]. Available from: https://www.cadth.ca/entrectinib-rozlytrek-ros1-positive-non-small-cell-lung-cancer (accessed: 03.04.2023).
Entrectinib (Rozlytrek) Scottish Medicines Consortium. 2021. Available from: https://www.scottishmedicines.org.uk/medicines-advice/entrectinib-rozlytrek-full-smc2294/ (accessed: 03.04.2023).
Это произведение доступно по лицензии Creative Commons «Attribution-NonCommercial-NoDerivatives» («Атрибуция — Некоммерческое использование — Без производных произведений») 4.0 Всемирная.
© АННМО «Вопросы онкологии», Copyright (c) 2023